The proposed pilot study will assess whether ingestion of a classic hallucinogen (psilocybin) leads to changes in emotion processing and neural circuitry that may predict repeated self-administration of this drug and underlie an atypical mechanism of abuse liability, which may vitally contribute to the understanding of the potential for abuse and the underlying mechanisms supporting abuse of classic hallucinogens.
Topic Healthy Subjects
Compound Psilocybin
Country United States of America
Visit trial
Status
Completed
Results Published
Yes
Start date
01 July 2017
End date
27 August 2018
Chance of happening
100%
Phase
Phase I
Phase II
Design
Open
Type
Interventional
Generation
First
Participants
13
Sex
All
Age
18- 45
Therapy
No
Trial Details
The proposed pilot study will assess whether ingestion of a classic hallucinogen (psilocybin) leads to changes in emotion processing and neural circuitry that may predict repeated self-administration of this drug and underlie an atypical mechanism of abuse liability, which may vitally contribute to the understanding of the potential for abuse and the underlying mechanisms supporting abuse of classic hallucinogens.NCT Number NCT02971605
Sponsors & Collaborators
Johns Hopkins UniversityJohns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.
National Institute on Drug Abuse
This company doesn't have a full profile yet, it is linked to a clinical trial.
Papers
Emotions and brain function are altered up to one month after a single high dose of psilocybinThis open-label (n=12) study investigated brain function (increased plasticity) and positive and negative affect. After a high dose of psilocybin (25mg/70kg), the positive effect increased and stayed elevated. Negative effects returned to normal at 1-month.